A phase I and pharmacokinetic study to determine the safety of ET-743 administered as a continuous intravenous infusion over 24 hours every 21 days in patients with soft tissue sarcoma.

Trial Profile

A phase I and pharmacokinetic study to determine the safety of ET-743 administered as a continuous intravenous infusion over 24 hours every 21 days in patients with soft tissue sarcoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2016

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 07 Oct 2015 New trial record
    • 28 Sep 2015 According to a Taiho Pharmaceutical media release, trabectedin 0.25 mg and 1 mg IV Infusion received marketing approval from the Ministry of Health, Labour and Welfare for the treatment of patients with soft tissue sarcoma in Japan. The results of this and two other trials supported this marketing approval.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top